Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/32901
Title: Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
Authors: STESSEL, Bjorn 
Vancuchelen, Charlotte
BRUCKERS, Liesbeth 
Geebelen, Laurien
CALLEBAUT, Ina 
VANDENBRANDE, Jeroen 
Pallens, Ben
Van Tornout, Michiel
Ory, Jean-Paul
van Halem, Karlijn
MESSIAEN, Peter 
HERBOTS, Lieven 
Ramaekers, Dirk
Dubois, Jasperina
Issue Date: 2020
Publisher: PERGAMON-ELSEVIER SCIENCE LTD
Source: Thrombosis Research, 194 , p. 209 -215
Abstract: Introduction: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome. Methods: In this mono-centric, controlled, before-after study, all consecutive adult patients with confirmed COVID-19 pneumonia admitted to ICU from March 13th to April 20th 2020 were included. A thromboprophylaxis protocol, including augmented LMWH dosing, individually tailored with anti-Xa measurements and twice-weekly ultrasonography screening for DVT, was implemented on March 31th 2020. Primary endpoint is one-month mortality. Secondary outcomes include two-week and three-week mortality, the incidence of VTE, acute kidney injury and continuous renal replacement therapy (CRRT). Multiple regression modelling was used to correct for differences between the two groups. Results: 46 patients were included in the before group, 26 patients in the after group. One month mortality decreased from 39.13% to 3.85% (p < 0.001). After correction for confounding variables, one-month mortality was significantly higher in the before group (p = 0.02, OR 8.86 (1.46, 53.75)). The cumulative incidence of VTE and CRRT was respectively 41% and 30.4% in the before group and dropped to 15% (p = 0.03) and 3.8% (p = 0.01), respectively. After correction for confounding variables, risk of VTE (p = 0.03, 6.01 (1.13, 32.12)) and CRRT (p = 0.02, OR 19.21 (1.44, 255.86)) remained significantly higher in the before group. Conclusion: Mortality, cumulative risk of VTE and need for CRRT may be significantly reduced in COVID-19 patients by implementation of a more aggressive thromboprophylaxis protocol. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. .
Notes: Stessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium.
bjorn.stessel@jessazh.be
Other: Stessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium. bjorn.stessel@jessazh.be
Keywords: COVID-19;Thromboprophylaxis;Venous thromboembolism;Mortality;Continuous renal replacement therapy
Document URI: http://hdl.handle.net/1942/32901
ISSN: 0049-3848
e-ISSN: 1879-2472
DOI: 10.1016/j.thromres.2020.07.038
ISI #: WOS:000568490100037
Rights: 2020 Elsevier Ltd. All rights reserved
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
1-s2.0-S0049384820303297-main.pdfPublished version558.17 kBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.